Statistical Modeling of Drug Half Lives

Advisor(s)

Dr. Tarek Mahfouz

Confirmation

1

Document Type

Poster

Location

ONU McIntosh Center; Activities Room

Start Date

24-4-2026 10:00 AM

End Date

24-4-2026 10:50 AM

Abstract

A drug’s elimination half-life (t ½ ) is defined as the time it takes for the plasma concentration of its pharmacologically active form to decline by 50%. It, therefore, is the factor to consider when determining the frequency of dosing. Drugs with long t ½ remain active for extended periods of time which corresponds to less frequent dosing and enhanced patient compliance. Accurately estimating the t ½ of drug candidates is, therefore, important in the drug design process because it helps reduce experimental cost and time by identifying unsuitable candidates early and focusing the search on those with reasonable duration of action. This research aims to develop a mathematical model that can accurately predict a drug’s t ½ using only structural information. Experimentally determined t ½ data were collected from drug databases for 98 approved drugs belonging to different therapeutic groups and spanning a broad range of t ½ , from short (≤2 hours) to long (≥100 hours). The dataset was divided into a training set for model development and optimization and a test set for external validation. A comprehensive set of structural descriptors was calculated for all drugs. For the training set, different groups of descriptors were incorporated into linear and non-linear modelling approaches to identify relationships between molecular features and t ½ . Statistical analyses were applied to identify the best performing models and these were used to calculate t ½ values for the test set. Computed t ½ values for the test set were then compared to the experimental values and the best performing models are presented.

This document is currently not available here.

Open Access

Available to all.

Share

COinS
 
Apr 24th, 10:00 AM Apr 24th, 10:50 AM

Statistical Modeling of Drug Half Lives

ONU McIntosh Center; Activities Room

A drug’s elimination half-life (t ½ ) is defined as the time it takes for the plasma concentration of its pharmacologically active form to decline by 50%. It, therefore, is the factor to consider when determining the frequency of dosing. Drugs with long t ½ remain active for extended periods of time which corresponds to less frequent dosing and enhanced patient compliance. Accurately estimating the t ½ of drug candidates is, therefore, important in the drug design process because it helps reduce experimental cost and time by identifying unsuitable candidates early and focusing the search on those with reasonable duration of action. This research aims to develop a mathematical model that can accurately predict a drug’s t ½ using only structural information. Experimentally determined t ½ data were collected from drug databases for 98 approved drugs belonging to different therapeutic groups and spanning a broad range of t ½ , from short (≤2 hours) to long (≥100 hours). The dataset was divided into a training set for model development and optimization and a test set for external validation. A comprehensive set of structural descriptors was calculated for all drugs. For the training set, different groups of descriptors were incorporated into linear and non-linear modelling approaches to identify relationships between molecular features and t ½ . Statistical analyses were applied to identify the best performing models and these were used to calculate t ½ values for the test set. Computed t ½ values for the test set were then compared to the experimental values and the best performing models are presented.